Phathom Pharmaceuticals (PHAT) Non-Current Deffered Revenue (2022 - 2026)

Phathom Pharmaceuticals (PHAT) has 5 years of Non-Current Deffered Revenue data on file, last reported at $347.9 million in Q1 2026.

• On a quarterly basis, Non-Current Deffered Revenue rose 1.19% year-over-year to $347.9 million in Q1 2026; TTM through Mar 2026 was $347.9 million, a 1.19% increase from a year earlier, with the FY2025 full-year figure at $350.1 million, up 5.06% from the prior year.
• Non-Current Deffered Revenue for Q1 2026 stood at $347.9 million, down from $350.1 million in the prior quarter.
• Over the last five years, Non-Current Deffered Revenue for PHAT reached as high as $350.1 million in Q4 2025 and fell as low as $109.5 million in Q4 2022.
• Historically, Non-Current Deffered Revenue has averaged $282.3 million across 5 years, with a median of $322.4 million in 2024.
• Across the five-year window, Non-Current Deffered Revenue jumped 173.74% in 2023 and climbed 1.19% in 2026, its largest moves.
• Year by year, Non-Current Deffered Revenue stood at $109.5 million in 2022, then jumped by 173.74% to $299.8 million in 2023, then increased by 11.16% to $333.3 million in 2024, then advanced by 5.06% to $350.1 million in 2025, then fell by 0.64% to $347.9 million in 2026.
• Per Business Quant data, the three most recent Non-Current Deffered Revenue figures were $347.9 million in Q1 2026, $350.1 million in Q4 2025, and $349.0 million in Q3 2025.